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Abstract
Background: Diabetes self-management education/training (DSME/DSMT) is a tool for
managing diabetes mellitus; however, a research gap exists regarding the clinical effectiveness of
completing versus failing to complete a DSME/DSMT program.
Objective: This study determined the difference in effectiveness between a single initial
individual DSMT session and completion of the full DSMT program via group classes by people
with type 2 diabetes.
Methods: A retrospective study compared HbA1c and lipid values between the “individual
education” and “group education” groups from pre- to post-program from the Presence St.
Joseph Medical Center’s DSMT program.
Results: Statistically significant differences were not found between groups for HbA1c or lipids
(p = 0.612). However, clinically significant differences were noted from pre- to post-program in
HbA1c and all lipid values in favor of the program-completing group.
Conclusions: This study supports the efficacy of program completion in guiding HbA1c and
lipid levels toward clinical targets when compared to the same laboratory values for noncompletion.

ii

Table of Contents
Abstract ..................................................................................................................................... ii
List of Tables ........................................................................................................................... vi
List of Figures .......................................................................................................................... vi
Chapter 1: Introduction ..............................................................................................................1
Background ....................................................................................................................1
Presence St. Joseph Medical Center Diabetes Self-Management Training Program ....3
Purpose of the Study ......................................................................................................4
Research Questions ........................................................................................................5
Justification for the Study ..............................................................................................5
Chapter 2: Review of Literature ................................................................................................6
Introduction to Diabetes .................................................................................................6
Pathology ...........................................................................................................6
Classifications ....................................................................................................7
Risk Factors .......................................................................................................8
Complications ....................................................................................................9
The Case for Glycemic Control ...........................................................10
The Relationship of Lipids...................................................................14
Diagnosis and Management .........................................................................................15
Diagnostic Criteria ...........................................................................................15
Management Strategies ....................................................................................16
Empowering the Patient: Diabetes Self-Management Education ................................17
Description .......................................................................................................17

iii

Program Efficacy .............................................................................................18
Clinical/Medical Benefits ....................................................................18
Patient-Centered Benefits ....................................................................20
Decreased Healthcare Costs .................................................................21
Dosage-Response to Education........................................................................23
Chapter 3: Research Design and Methodology .......................................................................24
Research Design...........................................................................................................24
Study Population ..........................................................................................................25
Ethics............................................................................................................................26
Study Time Frame........................................................................................................26
Data Analysis ...............................................................................................................26
Chapter 4: Research Results ....................................................................................................28
Demographics ..............................................................................................................28
Initial Pre- and Post-Program Observations ................................................................30
Pre-Program Comparisons ...........................................................................................35
Post-Program Comparisons .........................................................................................37
Pre- to Post-Program Between-Group Changes ..........................................................39
Chapter 5: Discussion ..............................................................................................................42
Question One: Was There a Significant Difference in the Average Degree of
Reduction in HbA1c Levels between Patients with T2DM Who Attended an
Individual Education Session versus Patients with T2DM Who Completed an
Individual Session and All Group Education Classes from Pre- to Post-Program? ....42
Question Two: Was There a Significant Difference in the Average Degree of
Reduction in Lipid Levels between Patients with T2DM Who Attended an
Individual Education Session versus Patients with T2DM Who Completed an
Individual Session and All Group Education Classes from Pre- to Post-Program? ....44

iv

Chapter 6: Conclusions ............................................................................................................48
Summary and Conclusions ..........................................................................................48
Limitations of the Study...............................................................................................50
Implications..................................................................................................................51
Future Research ...........................................................................................................52
References ................................................................................................................................54
Appendices...............................................................................................................................63
Appendix A: Eastern Michigan University Human Subjects Review Committee
Approval Letter ............................................................................................................64
Appendix B: Eastern Michigan University Human Subjects Review Committee
Continuing Approval Letter .........................................................................................65
Appendix C: PSJMC Institutional Review Board Approval Letter .............................66
Appendix D: DSMT Initial Visit Form........................................................................67

v

List of Tables
Table

Page

1. Categorical Demographic Characteristics for Gender, Race, and Previous Diabetes
Education by Education Group ....................................................................................29
2. Continuous Demographic Characteristics for Age, Height, Weight, and BMI by
Education Group ..........................................................................................................30
3. Pre-Program Comparisons for HbA1c (%), TC (mg/dl), HDL (mg/dl), LDL (mg/dl),
and TG (mg/dl) between Education Groups ................................................................37
4. Post-Program Comparisons for HbA1c (%), TC (mg/dl), HDL (mg/dl), LDL (mg/dl),
and TG (mg/dl) between Education Groups ................................................................38
5. Pre- to Post-Program Change Score Comparisons for HbA1c (%), TC (mg/dl), HDL
(mg/dl), LDL (mg/dl), and TG (mg/dl) between Education Groups ...........................40
6. Pre- and Post-Program Comparisons for HbA1c (%), TC (mg/dl), HDL (mg/dl), LDL
(mg/dl), and TG (mg/dl) between Education Groups ..................................................41
List of Figures
Figure

Page

1. Differences in HbA1c levels (%) Pre- and Post-Program for Individual (IE) and
Group Education (GE) .................................................................................................31
2. Differences in TC levels (mg/dl) Pre- and Post-Program for Individual (IE) and
Group Education (GE) .................................................................................................32
3. Differences in HDL levels (mg/dl) Pre- and Post-Program for Individual (IE) and
Group Education (GE) .................................................................................................33
4. Differences in LDL levels (mg/dl) Pre- and Post-Program for Individual (IE) and
Group Education (GE). ................................................................................................34
5. Differences in TG levels (mg/dl) Pre- and Post-program for Individual (IE) and
Group Education (GE) .................................................................................................35

vi

Chapter 1: Introduction
Background
Diabetes mellitus (DM), the disease associated with frequent episodes of abnormally high
blood glucose, has become an increasingly prevalent condition in the United States during the
past several decades. Recent estimates from the United States Centers for Disease Control and
Prevention (CDC) indicate that nearly 29.1 million people in the U.S. have diabetes; this
estimate includes both diagnosed (21.0 million) and undiagnosed (8.1 million) people, the sum of
which amounts to approximately 9.3% of the population (CDC, 2014). Diabetes is also
associated with a higher number of occurrences of the following complications: heart disease,
stroke, hypertension, blindness, kidney disease, nervous system diseases, amputations, and dental
diseases (CDC, 2014). Furthermore, the risk of death is increased nearly twofold for persons who
have diabetes in comparison to those who do not (CDC, 2014). Management of the disease is
therefore essential to preventing or delaying these complications.
Although diabetes is generally managed through a combination of strategies, including
pharmacotherapy and other medical care, diabetes education programs, frequently termed
Diabetes Self-Management Education (DSME) or Diabetes Self-Management Training (DSMT),
have recently become a vital part of comprehensive care (Jarvis, Skinner, Carey, & Davies,
2010; Steinsbekk, Rygg, Lisulo, Rise, & Fretheim, 2012). These programs, which are usually
conducted in an outpatient setting, provide practical management tips and techniques and serve
as a support for patients who struggle with handling their disease (Mendoza & Rosenberg, 2013).
Varying educational formats are used among programs, including individual counseling sessions,
group classes, and combinations of group and individual sessions (Mendoza & Rosenberg,
2013). Educational materials, topics discussed, and accreditation status of the program delivering
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the education may also vary (Mendoza & Rosenberg, 2013; Jarvis et al., 2010). However, DSME
programs continue to increase in number and are the subject of a growing body of research
(Jarvis et al., 2010).
Much of the available research focuses on outcomes related to completion of a DSME
program versus standard or usual care as obtained from the primary care provider’s office. A
small amount of research has addressed comparisons between differing methods of delivery of
the same content within programs, such as through a specified number of individual counseling
sessions with a diabetes educator versus the same number of group classes also taught by a
diabetes educator (Torres, Franco, Stradioto, Hortale, & Schall, 2009; Dalmau-Llorca, GarciaBernal, Aguilar-Martin, & Palau-Galindo, 2003; Campbell, Moffitt, & Sanson-Fisher, 1996;
Rickheim, Weaver, Flader, & Kendall, 2002), although these studies’ conclusions do not point to
a clear, consistent advantage of one type of educational format over another (Mendoza &
Rosenberg, 2013). Even further, studies comparing clinical outcomes of patients who have
partially versus fully completed a DSME program are quite rare and inconclusive (Liu, Lee, &
Brateanu, 2014). This area, a comparison of the impact of “dropouts” to compliant patients, is a
research gap that needs to be filled in order for future studies to target methods that could
increase patient attendance and compliance (Liu et al., 2014). Additionally, performing that
comparison in the context of a standardized, accredited/recognized DSME program, such as
those accredited or recognized by the American Association of Diabetes Educators (AADE) or
the American Diabetes Association (ADA), would assist with ensuring uniformity of education
provided.
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Presence St. Joseph Medical Center Diabetes Self-Management Training Program
The Presence St. Joseph Medical Center (PSJMC) Outpatient Clinic’s (Joliet, Illinois)
current DSMT program reopened in April 2014 after a several month hiatus and a full
restructuring of the educational curriculum. It is accredited by the AADE and is presided over by
a registered nurse (RN) who is also a certified diabetes educator (CDE). Newly enrolled patients
begin the program via an initial appointment with the CDE, also called the nurse educator.
During this appointment, several basic diabetes management concepts are covered (disease
process, hyperglycemia, target blood glucose numbers, glucometer usage, general healthy eating,
physical activity, and consistency in meal patterns), and the patient is then scheduled to attend a
series of three 2-hour classes at the facility within an approximately two-month time frame.
These classes cover the seven AADE diabetes self-care behaviors of healthy eating, being active,
monitoring, taking medication, problem solving, reducing risks, and healthy coping. Classes are
taught by the CDE, with one session guest-taught by a registered dietitian (RD). Patients may
also receive medical nutrition therapy (MNT) services from an RD while completing the
program; however, not all patients choose to do so, as it is an optional complement to the
program.
The pre- and post-program laboratory values hemoglobin A1c (HbA1c), total cholesterol
(TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and
triglycerides (TG) are requested from each patient’s primary care provider’s office to assist with
monitoring patient progress and providing outcomes data to the AADE. Those results are kept
both within individual patient charts as well as in the CDE’s program login on the AADE
website. To ensure relevance, the CDE specifies on each faxed request form that the most recent
laboratory values pre- and post-program should be sent for each patient. The usual time frame for
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the physician’s having collected these results is within one year pre- and post-program, although
post-program values have usually been collected within six months of the patient’s completing
the program.
Furthermore, during the past year, a fair percentage of patients who enrolled in the
DSMT program failed to complete it. While some of these patients attended the majority of
sessions, others attended only the initial individual session with the CDE. Upon preliminary
analysis, it appeared that this program contained sufficient “dropouts” to be compared with
patients who had completed the program. Laboratory values for these dropouts were also
available, as the same protocol is followed in obtaining all patients’ data regardless of whether
they have completed the program. To emphasize the extremes between groups and due to the
number of patient records available for comparison, it was decided to compare patients who had
attended only the initial individual session with those who had completed the entire program by
attending the initial session and all of the group classes.
Purpose of the Study
As the body of research regarding differences in effectiveness between patients who have
completed versus not completed DSME/DSMT programs is small, further quantitative research
was warranted in order to add to the current knowledge base and to provide diabetes educators
and program-accrediting associations with information for refinement of program materials and
standards to encourage continued patient participation and success. The purpose of this study
was to determine the degree of difference in effectiveness between a single individual counseling
session versus the completion of that session and all group diabetes education classes in the
outpatient setting as evidenced by HbA1c and lipid data from medical profiles of patients
diagnosed with type 2 diabetes mellitus (T2DM), who constitute the majority of patients with
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DM, in an AADE-accredited program. It was hypothesized that there would be a significant
degree of difference in effectiveness between the two groups with a greater degree of
improvement in laboratory values in the group that completed the entire program.
Research Questions
1.

Is there a significant difference in the average degree of reduction in HbA1c levels
between patients with T2DM who attended an individual education session versus
patients with T2DM who completed an individual session and all group education classes
from pre- to post-program?

2.

Is there a significant difference in the average degree of reduction in lipid levels between
patients with T2DM who attended an individual education session versus patients with
T2DM who completed an individual session and all group education classes from pre- to
post-program?

Justification for the Study
This study was designed to assess the impact of dropping out in relation to program
efficacy in an accredited DSME/DSMT program. Study results can be shared with other diabetes
centers currently accredited or recognized; these sites may use the data to judge how effective
their programs are and to use as a starting point for the further investigation of remedies to
patient compliance barriers. The findings also serve to demonstrate the effectiveness of AADEaccredited programs and add to the organization’s growing body of diabetes education research.
Lastly, the PSJMC Outpatient Clinic, where the study was conducted, gained quantitative data
pertaining to the effectiveness of its current DSMT program from its inception to the present.
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Chapter 2: Review of Literature
Introduction to Diabetes
Diabetes mellitus is a complex disease that continues to affect a greater percentage of the
world’s population as the years pass. The continuously increasing prevalence of DM demands
that healthcare practitioners achieve a solid understanding of the disease itself as well as its
currently practiced prevention and treatment methods. The following sections will provide an
overview of DM, from its development and classifications to its complications and treatment
options. The chapter will conclude with an explanation of the significance of diabetes education
programs in relation to disease management.
Pathology. A brief overview of normal food digestion and absorption provides the
necessary background against which the metabolic abnormalities of DM may be contrasted.
When food is consumed, it is chewed in the mouth, transported down the esophagus into the
stomach, churned in the stomach, and broken down even further in the small intestine into tiny
molecules that are absorbed into the bloodstream or the lymphatic system (Gropper & Smith,
2013). A molecule’s macronutrient type (either protein, fat, or carbohydrate) determines which
route it will take (Gropper & Smith, 2013). Carbohydrates, the main macronutrient of concern in
DM, are enzymatically broken down into single molecular units, the majority of which are
glucose, before being absorbed from the small intestine (Gropper & Smith, 2013). Glucose enters
the bloodstream and is transported to body cells where it is needed, such as those in the brain,
heart, liver, and skeletal muscles (Gropper & Smith, 2013). However, before glucose can enter
the cells, the hormone insulin, which is made by the pancreas, must attach to receptors on cells’
surfaces to trigger the response that allows entry (Gropper & Smith, 2013). After glucose enters
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the cell, it continues down specific pathways to be utilized for energy or stored as energy
reserves (Gropper & Smith, 2013).
In DM, however, glucose is unable to enter body cells due to either a lack of insulin, cell
receptor resistance to insulin’s action, or a combination of both events (American Diabetes
Association [ADA], 2014a). Glucose, in excess, remains in the bloodstream, where it eventually
bonds with proteins and lipids in an irreversible process called glycation (Goldin, Beckman,
Schmidt, & Creager, 2006). The end result of the series of reactions in the glycation process is
the production of advanced glycation end products (AGEs), which tend to build up and cause
damage to vascular tissue (Goldin et al., 2006), thus leading to vascular complications, including
heart attack, retinopathy, and kidney disease (CDC, 2014).
Classifications. Based on these mechanisms, DM is broadly classified as a metabolic
disease of the endocrine system in which defects in the secretion and/or action of the hormone
insulin result in hyperglycemia, or high blood sugar (ADA, 2014a). Insulin secretion defects are
often associated with pancreatic beta cell destruction as the result of an autoimmune response,
while insulin action defects are usually related to body tissues’ failure to respond to insulin and
may be seen in combination with decreased insulin production not stemming from an
autoimmune response (ADA, 2014a). One or both types of insulin defects may occur in
individuals, although one of the two faulty mechanisms is usually considered the primary
causative factor of the hyperglycemic response (ADA, 2014a). Therefore, DM has been
categorized into two main types based on etiology: type 1 diabetes mellitus (T1DM) and type 2
diabetes mellitus (T2DM) (ADA, 2014a).
Type 1 diabetes mellitus, which affects approximately 5% to 10% of people with DM, is
the result of sharply decreased insulin secretion due to the death of pancreatic beta cells caused
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by an autoimmune dysfunction (ADA, 2014a). Type 2 diabetes mellitus, by which 90% to 95%
of those with DM are affected, is caused by defective insulin action in relation to poor tissue
response, a phenomenon called insulin resistance (ADA, 2014a). Frequently found in
combination with insulin resistance are decreases in pancreatic beta cell number and mass,
possibly due to the presence of specific genes, and lessened suppression of the hormone
glucagon (Spellman, 2010).
Two other classes of DM exist, although they are seen far less frequently and have
differing causes (ADA, 2014a). Gestational diabetes mellitus (GDM) is described as glucose
intolerance that affects only pregnant mothers; it is usually resolved after the baby’s birth,
although it can develop into T2DM (ADA, 2014a). The “other specific types of diabetes”
category includes causes such as pancreatic disease, genetic defects in insulin action or beta-cell
function, drugs, infections, and endocrinopathies (ADA, 2014a; ADA, 2014b; ADA, 2015).
Risk factors. As the etiologies for each type of DM differ, risk factors follow a similar
pattern. Those related to T1DM include family history, environmental influences such as a virus,
geographic location, earlier-than-recommended exposure to foods like cow’s milk and cereal in
infancy, and the presence of diabetes-related autoantibodies (Mayo Clinic Staff, 2014). It should
be noted that these specific factors are generally outside the individual’s control, or nonmodifiable. In contrast, T2DM features a combination of non-modifiable and modifiable risk
factors, including family history, age, race, history of GDM, polycystic ovarian syndrome,
weight, physical inactivity, dyslipidemia, and hypertension (Mayo Clinic Staff, 2014). Risk
factors for GDM are similar to T2DM, including age, race, family history, and weight (Mayo
Clinic Staff, 2014). A cluster of generally modifiable risk factors called the metabolic syndrome,
or MetS, also heightens the risk for both T2DM and GDM (Gropper & Smith, 2013). Diagnosis
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of MetS necessitates the presence of at least three of the following five conditions: increased
waist circumference (≥40 inches for men, ≥35 inches for women), decreased HDL cholesterol
(<50 mg/dl in females, <40 mg/dl in males), increased triglycerides (≥150 mg/dl), increased
fasting blood glucose (≥100 mg/dl), and increased blood pressure (≥130/85 mm Hg) (Gropper &
Smith, 2013). Several of these criteria are also individual risk factors for DM. Especially for
T2DM and in part for GDM, the modifiable risk factors are those that are addressed in diabetes
prevention efforts.
Complications. As noted, the underlying characteristic of each type of DM is
hyperglycemia, the presence of excess glucose in the bloodstream. Increased blood levels of
glucose are believed to cause damage to vascular areas of the body via three main mechanisms:
oxidative stress, the production of AGEs and sorbitol, and direct endothelial damage by glucose
particles (Vithian & Hurel, 2010). The extent of the damage is great: blood flow in the blood
vessels is changed, excess proteins are deposited on blood vessel walls, increased coagulation
occurs, and endothelial permeability is altered (Vithian & Hurel, 2010). The resulting condition
of the blood vessels paves the way for various vascular diseases to occur (Vithian & Hurel,
2010). Two broad classifications currently categorize complications by the size of the blood
vessels that are affected: macrovascular and microvascular (Kanthardis, Wang, Carew, & Lan,
2011). Macrovascular complications include diseases of the cardiovascular and
peripherovascular systems, and microvascular complications include retinopathy, neuropathy,
and nephropathy (Kanthardis et al., 2011).
Statistics from the updated National Diabetes Statistics Report and the CDC display the
frequency and severity of these vascular complications in people with diabetes (CDC, 2014;
ADA, 2014c). Regarding macrovascular complications, statistics from 2010 indicate that both
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heart attack and stroke rates were amplified in adults with DM in comparison to adults without
the disease: heart attack rates were 1.8 times greater, and hospitalizations for stroke occurred 1.5
times more often (ADA, 2014c). Likelihood of death from cardiovascular disease (CVD) during
the years 2003 to 2006 was 1.7 times greater as well (ADA, 2014c). Furthermore, dyslipidemia,
a condition that heightens the risk of heart disease, was present in 65% of adults with DM during
the years 2009 through 2012 (ADA, 2014c). Hypertension, which also increases one’s risk of
heart disease, was present in 71% of people with DM during the same time period (ADA,
2014c).
Microvascular complications are prevalent in people with DM as well. During the years
2005 through 2008, 28.5% of the diabetic population experienced retinopathy, which can
eventually lead to irreversible loss of vision if not caught early enough (ADA, 2014c). Kidney
disease, or nephropathy, frequently leads to kidney failure, for which chronic dialysis or a kidney
transplant may be the only solutions (CDC, 2014). In 2011, 44% of kidney failure cases were
related to diabetes (ADA, 2014c). Furthermore, damage of the nervous system caused by
diabetes can result in loss of feeling in extremities and nerve diseases (CDC, 2014). For the most
severe cases, amputation may be the only means of correcting the issue (CDC, 2014)—73,000
diabetes-related amputations occurred in 2010 (ADA, 2014c). Dental disease, reduced immunity
to illness, decreased physical functional capacity, and depression are also found more often in
people with DM than those without it (CDC, 2014). These complications have great potential to
decrease a person’s quality of life.
The case for glycemic control. The following recent, large studies have explored the
relationship between vascular complications and glycemic control and have assisted with
providing the basis for government health organizations’ recommendations: the Action in
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Diabetes and Vascular Disease—Preterax and Diamicron Modified Release Controlled
Evaluation (ADVANCE) trial (ADVANCE Collaborative Group, 2008), the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) study (ACCORD Study Group, 2008), the Veterans
Affairs Diabetes Trial (VADT; Duckworth et al., 2009), the Diabetes Control and Complications
Trial (DCCT; DCCT Research Group, 1993), and the United Kingdom Prospective Diabetes
Study (UKPDS; UKPDS Group, 1998). Each study provided a unique contribution to the
knowledge regarding diabetes complications and glycemic control.
The ADVANCE study compared intensive glycemic control (modified release gliclazide
with the addition of other antihyperglycemic agents and/or insulin) to standard control (another
sulfonylurea or none at all) in 11,140 participants with T2DM and either a history of or risk
factor for macro- or microvascular disease (ADVANCE Collaborative Group, 2008). It did not
bring to light any significant differences in incidence of macrovascular risk between the two
groups (ADVANCE Collaborative Group, 2008). However, the intensive control group
displayed a significant (p = 0.01) 14% reduction in microvascular occurrences after achieving a
target HbA1c goal of 6.5% or lower (ADVANCE Collaborative Group, 2008).
The ACCORD study attempted to compare intensive glycemic control, defined as HbA1c
less than or equal to 6.0%, with normal glycemic control, defined as 7.0% to 7.9% HbA1c, in
10,251 middle-aged and older adults with T2DM and either established CVD or two risk factors
for CVD (ACCORD Study Group, 2008). However, the study was prematurely terminated 17
months prior to its scheduled end date due to an increased death rate in the intensive therapy
group (ACCORD Study Group, 2008). Results from the remaining time of the study did not
indicate significant differences in CVD events between groups in a three-year time frame,
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although the unanticipated increased risk of death was noted in the intensive therapy group
(ACCORD Study Group, 2008).
In the VADT, 1,791 military veterans with poorly controlled T2DM and risk factors for
and/or history of vascular complications were randomly assigned to either the standard control
group or an intensive therapy group (Duckworth et al., 2009). The mean HbA1c for all
participants was 9.4% at baseline, and mean time since diagnosis of T2DM was 11.5 years
(Duckworth et al., 2009). The intensive therapy group’s HbA1c was reduced to 6.9% after three
months through maximal dosages of two oral agents and insulin if necessary, while the standard
control group’s HbA1c reached 8.4% after three months with half dosages of two oral agents and
insulin if needed (Duckworth et al., 2009). At six-year follow-up, no significant differences in
rates of cardiovascular events, death, and microvascular complications were found between the
two groups (Duckworth et al., 2009).
In contrast to the three above-mentioned trials, the DCCT was carried out in a sample of
1,441 patients aged 13 to 39 years with insulin dependent DM (IDDM) and either no
complications or very mild retinopathy (DCCT Research Group, 1993). Both the intensive
control group and the standard control group were divided into subgroups of primary prevention
and secondary intervention in regards to retinopathy and microalbuminuria (DCCT Research
Group, 1993). After follow-up for a mean of six and one-half years, the intensive therapy group
as a whole displayed reduced risk and progression of microvascular complications by 35% to
over 70% (DCCT Research Group, 1993). At the end point, macrovascular complications were
collectively reduced in the intensive therapy group by 41%, although this number was not
considered statistically significant (DCCT Research Group, 1993).
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Lastly, the UKPDS in its initial phase studied 3,867 newly diagnosed patients with
T2DM who were either assigned to intensive treatment with varying oral agents (based upon
body mass index [BMI]) and/or insulin or a diet-only standard management approach with drugs
if absolutely necessary (UKPDS Group, 1998). Mean HbA1c after 10 years was reduced to 7.0%
in the intensive group versus 7.9% in the conventional control group (UKPDS Group, 1998). The
study demonstrated a significant (p = 0.0099) 25% reduction in risk for microvascular
complications but no significant reduction in macrovascular complications (UKPDS Group,
1998).
Interestingly, patients in both the DCCT and the UKPDS were monitored post-study in
two respective follow-up studies. Both follow-up studies provided contrasting results to those of
the originals in terms of cardiovascular outcomes. The Epidemiology of Diabetes Interventions
and Complications (EDIC) study, which was the 17-year follow-up to the DCCT, determined
that participants who had received intensive treatment reduced their risk of an initial
cardiovascular event by 42% (p = 0.02) and the first-time occurrence of myocardial infarction
(MI), stroke, and death from CVD, collectively, by 57% (p = 0.02) (Nathan et al., 2005).
Furthermore, microvascular risk reductions were sustained from the original trial (Nathan et al.,
2005). In the UKPDS, both categories of intensive treatment saw reductions in cardiovascular
risk over the long-term, defined as approximately 10 years (Holman, Paul, Bethel, Matthews, &
Neil, 2008). The sulfonylurea-insulin group demonstrated a 15% (p = 0.01) reduction in MI and
a 13% (p = 0.007) reduction in death from any cause, while in the metformin group there was a
39% (p = 0.01) decline in MI and a 36% (p = 0.01) decline in mortality (Holman et al., 2008). In
the intensive therapy group as a whole, the microvascular risk reductions from the original
intervention were also sustained (Holman et al., 2008).
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While the first three studies did not produce significant evidence that glycemic control
helps to lower the risk of CVD, the latter two suggest that cardiovascular benefits can still be
obtained through glycemic control in the long term (Skyler et al., 2009). However, glycemic
control is apparently quite effective in delaying microvascular complications, as several studies
have shown (Skyler et al., 2009). Due to these findings, the ADA, the American College of
Cardiology Foundation, and the American Heart Association (AHA) still advocate the
monitoring and control of cardiovascular risk status in combination with diabetes care and
glycemic control (Skyler et al., 2009).
The relationship of lipids. In addition to the recommendations for glycemic control, the
significance of serum lipid values should not go unnoticed. As people with DM are at an
increased risk of developing CVD, it follows that measures commonly used to assess CVD risk
and/or disease progress would be of utmost importance in these individuals. One specific
measure is the serum lipid profile. Endogenous lipids are transported in the bloodstream as
components of lipoproteins, which consist of protein, phospholipids, cholesterol, and
triglycerides (Gropper & Smith, 2013). The name of the lipoprotein depends on its composition
in terms of protein and lipid. High-density lipoproteins (HDL) contain a higher amount of
protein than lipid, while the reverse is true of low-density lipoproteins (LDL) (Gropper & Smith,
2013). Very-low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL)
follow the same pattern (Gropper & Smith, 2013). In relation to CVD, the end location of the
cholesterol transported by these lipoproteins is significant: LDL-transported cholesterol is
deposited in peripheral cells as well as in the vascular system, where, given time, it can build up
and contribute to the formation of artery-clogging plaques; in contrast, cholesterol carried by
HDL is taken away from these areas to the liver and eventually excreted via bile (Gropper &
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Smith, 2013). Thus, both an excess of LDL cholesterol and a lack of HDL cholesterol may be
damaging to the vascular system in the long term (Gropper & Smith, 2013). Both VLDL and
IDL are found in far lower concentrations in the bloodstream than HDL and LDL and as a result
are not significant contributors to CVD risk (Gropper & Smith, 2013).
Therefore, due to their concentrations and purposes, HDL and LDL cholesterol constitute
two of the most frequently measured serum lipid values. The other two commonly seen in the
lipid panel are triglycerides (TG) and total cholesterol (TC). Triglycerides consist of a glycerol
backbone with three attached fatty acids; they function as energy storage vessels (Gropper &
Smith, 2013). An excess of TG usually accompanies heart disease and may also be a causative
factor in its development (Do et al., 2013). Total cholesterol is the sum of HDL cholesterol, LDL
cholesterol, and approximately 20% of the TG concentration (American Heart Association
[AHA], 2014). Recommended values are as follows: TC: <200 mg/dl; HDL: >40 mg/dl in men,
>50 mg/dl in women; LDL: <100 mg/dl; TG: <150 mg/dl (Solano & Goldberg, 2006; Buse et al.,
2007).
Diagnosis and Management
Diagnostic criteria. In light of these statistics, diagnosis of DM becomes even more
important for prevention and/or treatment of its complications (CDC, 2014). Diagnostic
procedures often begin when a patient presents with any of the classic symptoms of diabetic
hyperglycemia: polydipsia, polyphagia, polyuria, blurred vision, and weight loss (ADA, 2014a;
van Belle, Coppieters, & von Herrath, 2011). The ADA’s diagnostic criteria are based upon
blood glucose levels (ADA, 2014a). Any one of the following positive test results, which are
usually repeated to ensure accuracy, allows for diagnosis (ADA, 2014a):
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•

Presentation of classic symptoms of hyperglycemia or a hyperglycemic crisis with a
random plasma glucose measuring ≥200 mg/dl (11.1 mmol/L). These results must occur
on at least two separate occasions.

•

A two-hour plasma glucose reading of ≥200 mg/dl (11.1 mmol/L) during an oral glucose
tolerance test (OGTT).

•

A fasting plasma glucose (FPG) reading of ≥126 mg/dl (7.0 mmol/L), where the fasting
period has been at least eight hours.

•

A HbA1c reading of ≥6.5%.
Historically, diagnosis has always been related to immediate blood glucose levels (ADA,

2014a). The exact numbers for diagnosis were even re-determined in 1997 after extensive testing
of the relationship of blood glucose levels to the presence of retinopathy (ADA, 2014a).
However, an indicator of more long-term levels has recently been accepted by the ADA in
addition to the current blood glucose readings: HbA1c (ADA, 2014a). Hemoglobin A1c, or
glycated hemoglobin, is the product of the binding of excess glucose in the bloodstream with the
red blood cell protein hemoglobin to form the compound glycated hemoglobin (Michigan
Diabetes and Research Training Center, 2014). As mentioned regarding the AGEs in the
complications section, this product is damaging to the vascular system (Michigan Diabetes and
Research Training Center, 2014). The greater the amount of glycated hemoglobin, the higher the
blood glucose levels have been; this measurement displays an average of one to three months’
worth of blood glucose levels, although it more accurately represents levels from the past two to
four weeks (Michigan Diabetes and Research Training Center, 2014).
Management strategies. As the recognition and diagnosis of DM have grown in recent
decades, management strategies have become a vital part of patient care (ADA, 2014b; ADA,
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2015). Medical practitioner involvement and pharmacotherapy are key components in the care
process (ADA, 2014b; ADA, 2015). Degree and type of practitioner care may vary based on the
situation but often includes MNT by an RD, psychosocial support, treatment or control of
comorbid conditions and complications, and regular physical assessments and screenings for
prevention of further complications (ADA, 2014b; ADA, 2015). Pharmacotherapy measures
include insulin therapy (for both T1DM and more severe cases of T2DM) and oral
antihyperglycemic agents, of which metformin is most often preferred (ADA, 2014b; ADA
2015). Regular blood samples (i.e., every six months, yearly, etc.) assist physicians with
adjusting dosages of these agents (ADA, 2014b; ADA, 2015).
Empowering the Patient: Diabetes Self-Management Education
Description. In addition to the previously mentioned methods of management, structured
diabetes education programs, specifically DSME/DSMT, have become a more widely used
means of providing support and reinforcement of key disease-management principles to persons
with DM, both in the United States and around the world (Jarvis et al., 2010; Steinsbekk et al.,
2012). They are generally based upon program standards created by either an international or
national diabetes-related organization, such as the International Diabetes Federation and the
United Kingdom’s Department of Health; the United States’ program standards are titled
“National Standards for Diabetes Self-Management Education” (Steinsbekk et al., 2012). In
general, the main objective of DSME is to facilitate a patient’s ability to confidently and
independently manage his or her disease (Steinsbekk et al., 2012). Programs, which are led by
trained medical professionals such as nurses or dietitians, may target one or both main types of
DM and include topics such as the development of coping skills, medication administration, diet,
exercise, problem solving, and blood glucose monitoring, to name a few (Mendoza &
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Rosenberg, 2013). Several formats are currently used for DSME programs, including individual
counseling sessions, group classes, and combinations of group and individual sessions (Mendoza
& Rosenberg, 2013).
Program efficacy. DSME programs do differ among themselves in various ways,
including educational materials used and topics covered, accreditation (or lack of) by diabetesrelated organizations such as the AADE and the ADA, population served, program format (e.g.
individual counseling, group education, a combination of group and individual sessions, other
types of special curricula), and ability/time frame in reference to patient follow-up (Mendoza &
Rosenberg, 2013; Jarvis et al., 2010). Programs’ success rates may differ from one another to a
small or large degree (Steinsbekk et al., 2012; Mendoza & Rosenberg, 2013). However, the
available literature displays an overall trend toward success as measured by disease management
outcomes as well as the likelihood of a promising future for these educational programs, since
DSME programs have become a large and vital presence in the medical realm today (Jarvis et al.,
2010). Further study of programs’ effectiveness both long- and short-term will also help to
provide more concrete information on various formats of diabetes education (Steinsbekk et al.,
2012). The following sections will provide an overview of DSME program effectiveness with a
focus on outcomes related to T2DM, which is the more commonly seen type of DM in patients
enrolled in most of these programs.
Clinical/medical benefits. Clinically, DSME programs have been linked with a reduction
in HbA1c in people with T2DM. Several recent studies and meta-analyses provide supporting
data for the same effect across multiple DSME formats. First, in a meta-analytic comparison of
group DSME versus either standard medical treatment, remaining on an education waiting list
while undergoing routine medical care, or non-DSME care based upon the diabetes standards of
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care, group DSME participants displayed a more significantly reduced HbA1c than participants
in the aforementioned control groups, which were collectively classified as usual care (Deakin,
McShane, Cade, & Williams, 2005). In the group DSME participants, a 1.4% (p < 0.00001)
greater reduction in HbA1c was seen at six months, a 0.8% (p < 0.00001) greater reduction was
visible at 12 months, and a 1.0% (p < 0.00001) greater reduction appeared at two years as
compared to the usual care control group (Deakin et al., 2005). In a recent update to that original
study, Steinsbekk et al. (2012) likewise identified significant reductions in HbA1c for those
enrolled in a group DSME program in comparison to those receiving usual care: 0.44% (p =
0.0006) reduction at six months, 0.46% (p = 0.001) reduction at 12 months, and 0.55% (p <
0.00001) reduction at two years. Second, nurse-led DSME programs with varying durations of
follow-up also demonstrated an ability to significantly decrease HbA1c (0.7% reduction) in
comparison to usual care (0.21% reduction) with a 0.48% (p < 0.001) net difference between the
two groups (Tshiananga et al., 2012). Similarly, a nurse-led telemedicine DSME program in a
rural community produced a significantly (p < 0.02) greater decrease in HbA1c than did usual
care in the same community at approximately three and six months post-program (Toledo,
Ruppert, Humber, & Siminerio, 2014). Finally, two more meta-analyses of multiple methods of
DSME indicated an average decrease in HbA1c: Norris and colleagues found a 0.76% greater
reduction immediately after program completion, 0.26% at one to three months, and 0.26% at
greater than four months in comparison to a control group of usual care (Norris, Lau, Smith,
Schmid, & Engelgau, 2002); and Gary and colleagues calculated a mean reduction of 0.43% (p <
0.003) from multiple educational and behavioral methods with varying durations of intervention
and follow-up (Gary, Genkinger, Gualiar, Peyrot, & Brancati, 2003).
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While not seen as often as HbA1c, the lipid profile has been included in some
comparative studies, which indicate that DSME programs may also be effective in assisting the
movement of lipid values toward normal limits without the use of medication. The
aforementioned nurse-led DSME program meta-analysis also included lipid values and noted
slight, yet non-significant, improvements in all of the lipid parameters as compared to usual care
(Tshiananga et al., 2012). Second, in a randomized clinical trial, a telehealth DSME program
administered by both a nurse and a dietitian in rural South Carolina resulted in a significant (p <
0.02) improvement in LDL cholesterol in participants at 12 months in comparison to others who
received usual care (Davis et al., 2010). Third, an extremely recent retrospective study of the
Cleveland Clinic’s AADE-accredited DSME program indicated significant decreases in TC (p =
0.01), LDL cholesterol (p = 0.02), and TG (p < 0.001) in addition to a significant (p < 0.001)
increase in HDL cholesterol pre- and post-program up to six months in patients who had
completed either three or four of the program’s educational sessions (Liu et al., 2014).
Furthermore, an association between DSME and reduced severity and/or delayed onset of
complications is generally accepted by the diabetes research community, although the evidence
does not appear to be firmly conclusive at this time (Clark, 2008). However, as was alluded to
earlier, because benefit has been found through glycemic control and intensive therapy in
reducing the impact of some vascular complications, the inclusion of these strategies as part of
DSME is likely advantageous and should continue (Skyler et al., 2009).
Patient-centered benefits. In addition to the marked impact on the above-mentioned
parameters, DSME has demonstrated the potential to assist patients with gaining a more positive
mindset and implementing healthier lifestyle behaviors (Powers et al., 2015). Several studies
report increases in participants’ perceptions of quality of life (Deakin et al., 2005; Cochran &
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Conn, 2008; Trento et al., 2004; Toobert et al., 2003) and decreases in depression (Hermanns et
al., 2015; de Groot et al., 2012) and diabetes-related distress (Fisher et al., 2013; Siminerio,
Ruppert, Huber, & Toledo, 2014). Improvements in coping skills (Tang, Funnell, & Oh, 2012;
Thorpe et al., 2013) and adherence to a healthy diet pattern (Tang et al., 2012; Toobert et al.,
2011) and exercise (Toobert et al., 2011) were also noted.
Decreased healthcare costs. The benefits discussion would be incomplete without
mentioning the cost-effectiveness aspect of DSME programs. Diabetes education is believed to
contribute to lowered healthcare costs through the alleviation of a portion of the need for care
related to diabetes complications as well as through a reduction in the number of hospital visits
accrued by patients who participate (Powers et al., 2015). Inpatient, outpatient, and community
programs have been the subjects of interest, although some studies only provide a basis for the
assumption while others actually estimate the healthcare costs. Criteria for inclusion were also
fairly heterogeneous among studies. For example, in the inpatient setting, a retrospective analysis
of data for 2,265 patients with poorly controlled diabetes (as demonstrated by a HbA1c >9%)
indicated a significantly decreased number of readmissions for patients who had received
inpatient diabetes education by CDEs as compared to patients who had not at both 30 (p =
0.0001) and 180 (p = 0.001) days; no costs were calculated in this study design (Healy, Black,
Harris, Lorenz, & Dungan, 2013).
The Urban Diabetes Study, which included 18,404 patients with diabetes who had
received outpatient medical care of any kind at the Philadelphia Health Care Centers, calculated
both costs and number of hospital readmissions (Robbins, Thatcher, Webb, & Valdmanis, 2008).
Patients who had attended one or more educational visits of select kinds (including diabetes
classes, nutritionist visits, and general health education) had a mean reduction of $11,571 per
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person-year (p < 0.001) in hospital-associated costs and a nine-visit hospitalization reduction per
100 person-years (p < 0.001) in comparison to those who had not attended an educational session
(Robbins et al., 2008). Patients who had attended at least one diabetes class had a mean reduction
of $6,913 per person-year in hospital costs and a five-and-one-half-visit hospitalization reduction
per 100 person-years; however, at p = 0.07 these numbers were not statistically significant
(Robbins et al., 2008).
In the community setting, community-health-worker-run programs for Hispanics with
T2DM seem to be cost effective (Prezio, Pagan, Shuval, & Culica, 2014; Brown et al., 2009). In
their analysis of data for 180 Hispanic patients with T2DM, Prezio et al. (2014) estimated a $355
medical cost per quality-adjusted life year for a 20-year time frame in 90 participants who had
participated in the educational program versus the 90 who had not. Similarly, using data from a
cohort of 6,551 Hispanic adults with T2DM, Brown et al. (2012) estimated a lifestyle
intervention cost range of $10,995 to $33,319 per quality-adjusted life year gained for 20 years.
Both estimates were deemed cost-effective as compared to the usual care estimate of $50,000
(Eddy, Schlessinger, & Kahn, 2005).
In addition to these studies, others have reached the same conclusions. Urbanski and
colleagues’ review of approximately 11 studies (five systematic reviews, two randomized
controlled trials, one controlled clinical trial, one longitudinal cohort study, one simulation
model, and one observational study) indicated that not all studies relating to cost-effectiveness of
DSME actually performed cost analyses (Urbanski, Wolf, & Herman, 2008). Those that did,
however, found some cost benefit, and the remaining studies suggested that cost benefit was
likely (Urbanski et al., 2008). Boren and colleagues’ review of DSME-related literature
classified 26 studies into three main categories based upon effects in terms of monetary savings
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or losses (Boren, Fitzner, Pahnalkar, & Specker, 2009). Out of 26 total studies, 18 were
associated with cost effectiveness, while the remainder indicated a neutral effect (four studies),
increased costs (one study), or an effect that did not fit in the three previous categories (three
studies) (Boren et al., 2009). The authors concluded that DSME programs are cost effective and
should continue to be tested as such to form firm conclusions on the topic (Boren et al., 2009).
Although the research may not be conclusive, it does appear to point to a positive view on the
cost effectiveness of DSME overall.
Dosage-response to education. One new area of interest in DSME research is dosageresponse to education (Duncan et al., 2011). While previous works have identified a correlation
between increasing hours of education and decreasing HbA1c, their heterogeneity in method and
educational focus is evident (Norris et al., 2002). Furthermore, at this time there is limited
research regarding clinical outcomes in accredited/recognized DSME/DSMT programs in
regards to number of sessions attended (Duncan et al., 2011). This study attempted to fill that
knowledge gap through a comparison of attendance at an initial education session versus
completion of an entire program of DSME/DSMT.
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Chapter 3: Research Design and Methodology
Research Design
A quantitative, retrospective study was conducted using existing data from the years 2014
and 2015 drawn from all qualifying patient medical records from the newly restructured DSMT
program at the Presence St. Joseph Medical Center (PSJMC) Outpatient Clinic (Joliet, Illinois).
The study determined the degree of difference in effectiveness between “individual” and “group”
diabetes education (the independent variable) through a comparison of average HbA1c and lipid
values pre- and post-program (the dependent variables) from patients who matched the
requirements for those educational categories. Placement in either education category was nonrandom and depended on the decisions of both the patient and the diabetes educator, who
delivered all educational sessions, thus making the study a quasi-experimental design.
Patient medical and program records are kept in both paper and electronic form in the
outpatient office. Records of all patients with any association to the diabetes and nutrition
programs are kept in paper form, while only the records of patients who have been enrolled in
the group classes (whether they actually attended or not) are included in the electronic records
within the AADE website under the nurse educator’s login. Therefore, the patients who attended
an initial appointment but chose not to enroll in the group classes are not included in the online
registry. The nurse educator is responsible for updating the online information as she updates it
in patients’ paper charts.
The medical records were divided into two groups based on the type of education
received in the DSMT program as notated within each record. One group contained patients who
participated only in a single initial individual DSMT counseling session, the individual education
group (IE), which is a precursor to class enrollment. Patients in this group received no further
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education in the program. The other group included patients who had attended both the initial
individual education session as well as all DSMT classes, the group education group (GE), for a
total of three 2-hour classes. Classes are held every other week, and the patient may choose
either a morning or afternoon session to accommodate his or her schedule. Thus, one rotation
through the cycle of three classes takes approximately one and one-half months. Data were
obtained from each patient’s medical record and entered into an Excel spreadsheet under the
category of “individual education” or “group education,” depending on the type of education the
patient had received. Values collected from each record included height, weight, BMI, age, race,
gender, notation of previous diabetes education, HbA1c levels pre- and post-education, and lipid
panel (TC, HDL, LDL, and TG) pre- and post-education. Medication information, details of
disease progression, and post-program BMI were not always available within each record and
therefore, were not collected.
Study Population
The study population included all patients with T2DM who had completed either an
initial individual diabetes education appointment or the full program of an individual
appointment plus all group diabetes education classes at the PSJMC Outpatient Clinic and whose
medical records were available from the facility. At the time of entry into their respective
programs, participants must have been at least 18 years of age or older with either a recent or
past diagnosis of T2DM. Additionally, patients must have either completed the program in its
entirety through group classes (in addition to the initial individual session) or have received only
the initial individual session.
Criteria for exclusion included patients who were under 18 years of age when they
enrolled in the program; patients with pre-diabetes, GDM, T1DM, or diabetes with an etiology
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other than that of T2DM; patients in the GE category who did not complete the program in its
entirety; and patients who were found to be deceased. Data were extracted from approximately
136 patient records.
Ethics
No live subjects were used in the study. All laboratory values and relevant demographic
information were obtained by the PI from the hospital outpatient center’s medical records; at no
time did the PI perform any medical tests or laboratory procedures. All collected patient data
were related to individual medical record numbers, which were de-identified to safeguard
sensitive patient information. No other personal identifiers were used. All medical records
remained in a locked office in the diabetes center, and all electronic data were password
protected on the PI’s computer. All identifiable data were destroyed at the conclusion of the
study.
Study Time Frame
The data were collected on site at PSJMC after approval from both Eastern Michigan
University’s Human Subjects Review Committee (Appendix A and B) and the PSJMC
Institutional Review Board (Appendix C) was granted. Collection time took approximately three
months.
Data Analysis
Data were analyzed with the assistance of a statistical consultant using SPSS statistical
software (SPSS release 22.0, 2013, IBM Corporation, Armonk, NY). Boxplots were created to
provide an initial visual impression of central tendency and variability of the five dependent
variables 1) between groups at baseline (also termed “pre-program”) and post-program and 2)
within groups from pre- to post-program. After correction for outliers, multivariate analysis of

26

variance (MANOVA) was run to determine whether significant (p < 0.05) differences existed
between groups at baseline and post-program. MANOVA was furthermore used to determine
whether significant differences in change scores (i.e., the mean difference from pre- to postprogram for each variable) existed between groups. Significant MANOVAs were followed by
separate t-tests for each variable with a Bonferroni adjustment added to reduce the risk of Type I
error. As there were five dependent variables, t-tests were therefore considered significant at p <
0.01. Results were finally compared to the clinical target values for diabetes-related standards of
care.
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Chapter 4: Research Results
Demographics
From April 2014 to April 2015, 136 patient records met the established criteria, with 64
patients in the IE group and 72 patients in the GE group. The total number of records from the
program was approximately 345; however, the records not included in the analysis consisted of
patients with GDM, patients who had attended only one or two group classes, patients who had
just begun or were in the process of completing the program during the data collection period,
and two patients who were deceased. Within the qualifying medical records, availability of preand post-program HbA1c and lipid data ranged from 37% to 78% in the IE group and 64% to
87% in the GE group.
As presented in Table 1, the two groups were similar in composition for the categorical
variables of gender (p = 0.390) and race (p = 0.517). As for diabetes education, seven patients in
the GE group (9.80%) reported previous education; interestingly, only one reported attending a
formal DSME/DSMT program several decades ago, and most could not remember any details of
the previous education such as date and number of sessions. Three patients were unsure if they
had even received education from a health professional but still answered “yes” to that question
on the introductory DSMT self-assessment form that all patients fill out prior to beginning the
program (Appendix D).
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Table 1
Categorical Demographic Characteristics for Gender, Race, and
Previous Diabetes Education by Education Group
IE
GE
(n = 64)
(n = 72)
n
% of Total
n
% of Total
Gender
Female
32
50.00
40
55.60
Male
32
50.00
32
44.40
Race
White
31
48.44
45
62.50
Black
16
25.00
14
19.44
Hispanic
14
21.88
10
13.89
Asian
1
1.56
0
0.00
Other
2
3.13
3
4.17
Previous Education
No
64
100.00
65
90.30
Yes, once
0
0.00
4
5.60
Yes, once/unsure
0
0.00
3
4.20
Note. When added, total percentages may slightly exceed 100% due to rounding.
Abbreviations: IE, individual education; GE, group education.

However, as shown in Table 2, significant differences between groups emerged for the
continuous variables of age (p < 0.01), weight (p < 0.05), and BMI (p < 0.05) but not for height
(p = 0.280). Participants in the IE group were approximately 6.86 years younger on average but
had a higher mean weight (mean difference = 22.86 pounds) and BMI (mean difference = 2.86
kg/m2) than those in the GE group. Furthermore, although the average BMI in each group would
be classified in the general obesity category, a differentiation in subcategories of obesity exists
between the two groups, with the IE group’s mean BMI of 36.27 kg/m2 considered class 2
obesity (BMI of 35.0 to 39.9 kg/m2) and the GE group’s mean BMI of 33.41 kg/m2 considered
class 1 obesity (BMI of 30 to 34.9 kg/m2) (Nelms, Sucher, Lacey, & Roth, 2011).
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Table 2
Continuous Demographic Characteristics for Age, Height, Weight, and BMI by Education Group
IE (n = 64)
GE (n = 72)
n

Min

Max

m

SD

n

Min

Max

m

SD

Pvalue

Age, yrs.

64

25.00

74.00

52.22

11.65

72

34.00

92.00

59.08

12.82

<0.01

Height, in.

64

59.00

74.00

67.02

3.78

72

57.00

77.00

66.22

4.65

0.280

64

94.00

418.00

231.86

57.60

72

133.00

385.00

209.00

54.13

<0.05

Weight, lbs.
2

BMI, kg/m
64
16.10
57.80
36.27
8.48
72
22.70
55.20
33.41
7.37 <0.05
Note. Decimal numbers are rounded to the nearest tenth. Abbreviations: IE, individual education; GE, group
education; m, mean; SD, standard deviation.
P-values delineate the degree of difference between the IE and GE groups for each variable. P-values are
considered significant at p = 0.01.

Initial Pre- and Post-Program Observations
The pre- and post-program dependent variables—HbA1c and lipids—were first analyzed
using a boxplot to determine central tendency and distributional qualities (Figures 1–5). Preprogram median HbA1c, TC, HDL, LDL, and TG were noted to be slightly higher in the IE
group in comparison to the GE group. Post-program median HbA1c, TC, LDL, and TG remained
higher in the IE group than in the GE group, while median HDL appeared lower in the IE group
than in the GE group.
Within groups, median HbA1c decreased in both the IE and GE groups from pre- to postprogram, while median TC and LDL appeared to remain fairly constant in both groups. Median
HDL decreased pre- to post-program in the IE group, while a slight rise was noted in the GE
group. Lastly, median TG appeared to rise in the IE group and decrease in the GE group from
pre- to post-program.
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Figure 1. Differences in HbA1c levels (%) pre- and post-program for individual (IE) and group
education (GE). In this figure, “individual” corresponds to IE, and “group” corresponds to GE.
Outliers are represented by circles. The number associated with each outlier corresponds to its
line number in the statistics software database. The horizontal line within each box corresponds
to the median value.
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Figure 2. Differences in TC levels (mg/dl) pre- and post-program for individual (IE) and group
education (GE). In this figure, “individual” corresponds to IE, and “group” corresponds to GE.
Outliers are represented by circles. The number associated with each outlier corresponds to its
line number in the statistics software database. The horizontal line within each box corresponds
to the median value.
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Figure 3. Differences in HDL levels (mg/dl) pre- and post-program for individual (IE) and group
education (GE). In this figure, “individual” corresponds to IE, and “group” corresponds to GE.
Outliers are represented by circles. The number associated with each outlier corresponds to its
line number in the statistics software database. The horizontal line within each box corresponds
to the median value.
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Figure 4. Differences in LDL levels (mg/dl) pre- and post-program for individual (IE) and group
education (GE). In this figure, “individual” corresponds to IE, and “group” corresponds to GE.
Outliers are represented by circles. The number associated with each outlier corresponds to its
line number in the statistics software database. The horizontal line within each box corresponds
to the median value.
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Figure 5. Differences in TG levels (mg/dl) pre- and post-program for individual (IE) and group
education (GE). In this figure, “individual” corresponds to IE, and “group” corresponds to GE.
Outliers are represented by circles, and extreme outliers are represented by asterisks. The number
associated with each outlier corresponds to its line number in the statistics software database.
The horizontal line within each box corresponds to the median value.
Pre-Program Comparisons
Following boxplot analysis and correction for outliers, MANOVA was employed to
determine between-group differences in the dependent pre-program variables. A significant (p <
0.001) Box’s M test of the variance-covariance homogeneity assumption necessitated the use of
Pillai’s Trace to more reliably estimate significance. This method produced a significant (p =
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0.008) MANOVA result, and subsequent t-tests with a Bonferroni adjustment for each variable
were required.
Results from the t-tests were not uniform in terms of significance, as shown in Table 3.
Beginning with HbA1c, although the mean level was slightly higher in the IE group (n = 50)
than in the GE group (n = 63), the difference between groups (mean difference = 0.30%, SE =
0.42) was not significant (p = 0.470). In contrast, there was a significant (p = 0.002) difference
between groups for TC (mean difference = 26.45 mg/dl, SE = 8.29), with a notably higher level
in the IE group (n = 41) than in the GE group (n = 54). HDL measurements did not demonstrate
a significant (p = 0.907) difference between groups (mean difference 0.32 mg/dl, SE = 2.77), as
the IE group (n = 41) showed only a very slightly lower average than the GE group (n = 54). A
significant (p < 0.001) difference was found in LDL between groups (mean difference = 32.94
mg/dl, SE = 7.40), as participants in the IE group (n = 40) displayed a notably higher average
than the GE group (n = 51). Last, no significant (p = 0.764) difference was found in TG values
between groups (mean difference = 5.96 mg/dl, SE = 19.79), although the IE group (n = 41) had
a slightly lower mean value than the GE group (n = 54).

36

Table 3
Pre-Program Comparisons for HbA1c (%), TC (mg/dl), HDL (mg/dl), LDL (mg/dl), and TG (mg/dl) between
Education Groups
IE (n = 64)a

GE (n = 72)b

P-value

n

Min

Max

m

SD

n

Min

Max

m

SD

HbA1c, %

50

5.50

15.65

8.83

2.56

63

5.50

13.80

8.52

1.89

0.470

TC, mg/dl

41

119.00 276.70 194.30

43.32

54

86.00

244.00 167.85

37.32

0.002

HDL, mg/dl

41

16.00

82.00

44.27

13.19

54

14.00

79.00

44.59

13.55

0.907

LDL, mg/dl

40

60.00

197.35 121.47

38.07

51

29.00

165.00

88.53

32.51

<0.001

TG, mg/dl

41

49.00

376.80 168.92

87.48

54

43.00

421.75 174.88 101.21

0.764

Note. Decimal numbers are rounded to the nearest tenth. Abbreviations: IE, individual education; GE, group
education; HbA1c, hemoglobin A1c; TC, total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, lowdensity lipoprotein cholesterol; TG, triglycerides; m, mean; SD, standard deviation.
a,b
Not all laboratory values were obtainable for each patient; thus the numbers presented do not equal the total
number of patients in each group.
P-values delineate the degree of difference between the IE and GE groups for each variable. P-values are
considered significant at p = 0.01.

As compared to clinical boundaries, pre-program mean HbA1c in both groups measured
higher than the target value of 7% or less for people with DM (Buse et al., 2007) by 1.83% for
the IE group and 1.52% in the GE group. Mean TC, in contrast, was below the <200 mg/dl target
(Solano & Goldberg, 2006; Buse et al., 2007) in both groups by 5.7 mg/dl in the IE group and
32.15 mg/dl in the GE group. HDL was not compared to clinical targets, seeing as analyses by
gender were not performed. LDL results contrasted between groups—while the IE group’s mean
value rose above the <100 mg/dl goal (Solano & Goldberg, 2006; Buse et al., 2007) by 21.47
mg/dl, the GE group’s mean value measured below the target by 11.47 mg/dl. TG values
exceeded the recommended goal of <150 mg/dl (Solano & Goldberg, 2006; Buse et al., 2007) in
both groups by 18.92 mg/dl in the IE group and 24.88 mg/dl in the GE group.
Post-Program Comparisons
Post-program data similarly led to a significant (p < 0.001) Box’s M test, which again
required the use of Pillai’s Trace; this MANOVA result was significant (p = 0.002). The
subsequent t-tests with a Bonferroni adjustment also displayed mixed results, as presented in
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Table 4. The difference in HbA1c (mean difference = 0.79%, SE = 0.30) was insignificant (p =
0.011), although the mean value for the IE group (n = 38) did appear substantially higher than
that of the GE group (n = 58). A significant (p = 0.007) difference in TC values (mean difference
= 21.31 mg/dl, SE = 7.61) did appear between the two groups, with a higher post-program level
in the IE group (n = 24) than in the GE group (n = 46). The difference in HDL (mean difference
= 3.60 mg/dl, SE = 3.18) was not significant (p = 0.262), but participants in the IE group (n = 24)
ended the program with a lower average than did GE participants (n = 46). Similarly to HbA1c,
LDL values exhibited a non-significant (p = 0.016) but still substantial difference between
groups (mean difference = 17.15 mg/dl, SE = 6.97), with a higher mean value in the IE group (n
= 24) than in the GE group (n = 45). Finally, TG displayed a pattern similar to that of HbA1c and
LDL, with a non-significant (p = 0.034) yet large difference between groups (mean difference =
46.85 mg/dl, SE = 21.70) and a higher mean value in the IE group (n = 24) than in the GE group
(n = 46).
Table 4
Post-Program Comparisons for HbA1c (%), TC (mg/dl), HDL (mg/dl), LDL (mg/dl), and TG (mg/dl) between
Education Groups
IE (n = 64)a
GE (n = 72)b
Pvalue
n
Min
Max
m
SD
n
Min
Max
m
SD
HbA1c, %
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TC, mg/dl

24

HDL, mg/dl
LDL, mg/dl

5.50

12.95

7.66

1.95

58

5.20

117.00 255.00 188.83

33.44

46

24

22.00

66.00

43.71

12.57

24

48.00

186.25 107.51

33.04

9.06

6.87

1.01

0.011

86.00

222.00 167.52 28.47

0.007

46

23.00

82.60

47.31

12.68

0.262

45

26.00

136.00

90.36

24.21

0.016

TG, mg/dl
24
58.00 542.75 194.91 106.48
46
47.00 335.20 148.05 73.64 0.034
Note. Decimal numbers are rounded to the nearest tenth. Abbreviations: IE, individual education; GE, group
education; HbA1c, hemoglobin A1c; TC, total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, lowdensity lipoprotein cholesterol; TG, triglycerides; m, mean; SD, standard deviation.
a,b
Not all laboratory values were obtainable for each patient; thus the numbers presented do not equal the total
number of patients in each group.
P-values delineate the degree of difference between the IE and GE groups for each variable. P-values are
considered significant at p = 0.01.
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Clinically, post-program laboratory values for the two groups differed in regards to
reaching established goals. As for HbA1c, the IE group’s mean value remained above 7% by
0.66%, while the GE participants’ mean value met the target of less than 7% (Buse et al., 2007)
at 6.87%, a 0.13% difference. As for TC, both groups’ mean values were under the
recommended <200 mg/dl target (Solano & Goldberg, 2006; Buse et al., 2007) by 11.17 mg/dl
for IE and 32.48 mg/dl for GE. Again, HDL cholesterol could not be compared clinically. Mean
LDL exceeded the <100 mg/dl target (Solano & Goldberg, 2006; Buse et al., 2007) by 7.51
mg/dl in the IE group but averaged below that target in the GE group by 9.64 mg/dl. Lastly, TG
exceeded the <150 mg/dl goal (Solano & Goldberg, 2006; Buse et al., 2007) in the IE group by
44.91 mg/dl but measured less than the goal value in the GE group by 1.95 mg/dl.
Pre-to Post-Program Between-Group Changes
Lastly, pre- to post-program change scores for each dependent variable (Table 5) were
calculated and compared between the two groups using MANOVA. Data used to calculate the
change scores were taken from records of patients who had both pre- and post-program
laboratory values available for each variable. Therefore, change score calculations did not
include data from all the patient records that were included in the pre- and post-program
comparisons. As Box’s M test was not significant (p = 0.151), which indicated that the variancecovariance homogeneity assumption was met, the MANOVA results from Wilk’s Lambda were
used. These values (Wilks’ Lambda = 0.901, F(5, 33) = 0.722, p = 0.612, partial η2 = 0.099)
indicated that no significant differences existed between groups in degree of change for any of
the dependent variables pre- to post-program. Due to the insignificant result from MANOVA,
further t-tests were unnecessary.
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Table 5
Pre- to Post-Program Change Score Comparisons for HbA1c (%), TC
(mg/dl), HDL (mg/dl), LDL (mg/dl), and TG (mg/dl) between Education
Groups
IE (n = 64)
GE (n = 72)
Complete
Complete
Change Score
Change Score
Records
Records
n
m ± SD
n
m ± SD
HbA1c, %
26
–1.39 ± 2.70
50
–1.53 ± 1.83
TC, mg/dl
16
–5.86 ± 40.36
34
–5.18 ± 26.74
HDL, mg/dl
16
0.00 ± 8.70
34
+2.04 ± 8.69
LDL, mg/dl
15
–9.30 ± 9.30
31
–4.90 ± 24.83
TG, mg/dl
16
+18.13 ± 116.00
34
–24.51 ± 62.81
Note. Decimal numbers are rounded to the nearest tenth. The change score
calculation used only values from patients whose records contained complete
pre- and post-program data, unlike the mean calculated for each pre- and postprogram variable. N = the number of records with complete pre- and postprogram information available for each variable. A “+” sign before the mean
indicates that the average degree of change moved in an upward direction, or
rose in value; while a “–” sign before the mean indicates a decrease, or
downward change in direction of the value. Abbreviations: IE, individual
education; GE, group education; HbA1c, hemoglobin A1c; TC, total
cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low-density
lipoprotein cholesterol; TG, triglycerides; m, mean; SD, standard deviation.

However, a comparison of both groups’ pre- to-post-program values as a whole (Table 6)
does highlight some important clinical changes. In terms of HbA1c, both groups began above
and made progress toward the goal of <7% (Buse et al., 2007) although only the GE group ended
with an average value in accordance with the target, at 0.13% below the <7% goal. Mean pre- to
post-program decreases were 1.17% for the IE group and 1.65% for the GE group. As for TC,
both groups began and ended the program with mean values within the target limit of <200
mg/dl (Solano & Goldberg, 2006; Buse et al., 2007); the decrease was slightly more noticeable in
the IE group (-5.47 mg/dl) than in the GE group (-0.33 mg/dl). HDL was shown to decrease very
slightly in the IE group (-0.56 mg/dl) and increase slightly in the GE group (+2.72 mg/dl); these
results were not compared to clinical targets. LDL decreased in the IE group from pre- to postprogram (-13.96 mg/dl) but remained above the target value of <100 mg/dl (Solano & Goldberg,
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2006; Buse et al., 2007) at both points of measure, while it increased slightly in the GE group
(+1.83 mg/dl) but still remained under the target value at both pre- and post-program. Lastly, TG
in the IE group measured above the <150 mg/dl target (Solano & Goldberg, 2006; Buse et al.,
2007) both pre- and post-program and actually increased during that time frame (+25.99 mg/dl),
while TG in the GE group decreased by 26.83 mg/dl from a level above the target to a value that
was below the target by 1.95 mg/dl.

Table 6
Pre- and Post-Program Comparisons for HbA1c (%), TC (mg/dl), HDL (mg/dl), LDL
(mg/dl), and TG (mg/dl) between Education Groups
IE (n = 64)a

GE (n = 64)b

Pre-Program

Post-Program

Pre-Program

Post-Program

m ± SD

m ± SD

m ± SD

m ± SD

HbA1c, %

8.83 ± 2.56

7.66 ± 1.95

8.52 ± 1.89

6.87 ± 1.01

TC, mg/dl

194.30 ± 43.32

188.83 ± 33.44

167.85 ± 37.32

167.52 ± 28.47

HDL, mg/dl

44.27 ± 13.19

43.71 ± 12.57

44.59 ± 13.55

47.31 ± 12.68

LDL, mg/dl

121.47 ± 38.07

107.51 ± 33.04

88.53 ± 32.51

90.36 ± 24.21

TG, mg/dl

168.92 ± 87.48

194.91 ± 106.48

174.88 ± 101.21 148.05 ± 73.64

Note. Decimal numbers are rounded to the nearest tenth. Abbreviations: IE, individual education;
GE, group education; HbA1c, hemoglobin A1c; TC, total cholesterol; HDL, high-density
lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglycerides; m, mean;
SD, standard deviation.
a,b
Not all laboratory values were obtainable for each patient; thus the numbers presented do not
equal the total number of patients in each group.
P-values comparing change scores between groups were not calculated for each variable, as the
MANOVA result did not demonstrate a significant difference between groups in degree of
change.
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Chapter 5: Discussion
Question One: Was there a significant difference in the average degree of reduction in
HbA1c levels between patients with T2DM who attended an individual education session
versus patients with T2DM who completed an individual session and all group education
classes from pre- to post-program?
A statistically significant difference in reduction of HbA1c levels was not found between
groups in this study, contrary to the original hypothesis. However, clinical differences were
nonetheless noted between groups post-program (Table 4) and within groups from pre- to postprogram (Table 6), observations that seem to support the purported pattern of a dose-response
relationship between hours of diabetes education received and degree of change in DM-related
laboratory values (Norris et al., 2002; Duncan et al., 2011). Whereas pre-program HbA1c
concentrations were quite similar between the two groups with only a 0.30% mean difference
(Table 3), post-program levels demonstrated a difference of 0.79% between groups (Table 4),
which was a notable clinical difference in relation to the recommended target goal of <7% (Buse
et al., 2007): Mean post-program HbA1c in the IE group declined from its pre-program value of
8.83% but remained above the <7% target at 7.66% (Table 6), while mean HbA1c in the GE
group decreased from a pre-program value of 8.52% and was reduced below the <7% target
value to 6.87% (Table 6).
Although the GE group displayed a larger degree of reduction in HbA1c level than the IE
group, both groups’ mean values did decrease by greater than one percentage point, a reduction
that is believed to lower the risk of micro- and macrovascular complications to some degree
(Stratton, Adler, & Neil, 2000). Further analysis of data from the UKPDS trial demonstrated that
a 1% reduction in HbA1c over 10 years was associated with risk reductions of 14% for
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myocardial infarction, 37% for microvascular complications, and 21% for diabetes-related death
(Stratton et al., 2000). Therefore, both groups in this study did appear to have obtained some
benefit from their respective quantities of education; and if post-program HbA1c levels are
sustained in the long term, participants in both groups might expect percentages of risk reduction
for vascular complications that are similar to those in the UKPDS trial (Stratton et al., 2000).
However, the greater change seen in the GE group should not be minimized, as this
group attained a mean post-program value in accordance with the <7% clinical target as
recommended in the diabetes standards of care (Buse et al., 2007). Based upon evidence
presented by Norris et al. (2002) that correlated a decrease in HbA1c levels with an increase in
hours of diabetes education received, this result would be expected, especially since diabetes
education programs that emphasized lifestyle interventions were the main focus of the metaanalysis. In the same meta-analysis, even patients who had received any quantity of diabetes
education still displayed a greater overall reduction in HbA1c than patients in the control groups
who had received usual care from their providers (Norris et al., 2002). Additionally, as implied
from the parallel relationship between decreased HbA1c and reduced risk for vascular
complications as demonstrated in the UKPDS trial (Stratton et al., 2000), the lowering of HbA1c
to the clinically significant level of <7% (Buse et al., 2007) would likely heighten the health
benefits received from completing the program, contrasting with a smaller projected degree of
risk reduction that would be expected for participants who failed to complete the program.
Furthermore, due to the presence of such a clinically significant change between groups,
the positive impact of quality diabetes education upon HbA1c values (Norris et al., 2002) is
supported by this study. Though other factors may have affected the outcomes, such as
medication dosage, it appears likely that program completion and overall patient compliance to
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the educational recommendations are related, thus resulting in the changes noted. A comparable
observation was reported by Duncan et al. (2011), who found that increases in compliance
behaviors, such as adherence to medication regimen and follow-up with providers, corresponded
with a higher number of hours of diabetes education. Although it is unknown as to what factors
may have directly influenced compliance in this study, it is highly possible that the group class
format encouraged success through the social connection with peers, a relaxed and interactive
classroom atmosphere, and the opportunity to invite family members to classes for additional
support. Those in the IE group, who did not attend these classes, could not have reaped the
benefits from them. One important ramification from this finding is the potential for savings in
healthcare costs, especially for patients who completed the program, as increased compliance to
educational recommendations is associated with fewer inpatient hospital costs and thus a lower
overall healthcare cost average long-term in patients with T2DM (Duncan et al., 2011).
Question Two: Was there a significant difference in the average degree of reduction in lipid
levels between patients with T2DM who attended an individual education session versus
patients with T2DM who completed an individual session and all group education classes
from pre- to post-program?
As with HbA1c, no statistically significant differences were found between groups in
lipid values pre- to post-program, although several other statistical and clinical differences do
deserve mention. Beginning with TC, mean pre-program values in both groups (Table 3) were
below the target value of <200 mg/dl (Solano & Goldberg, 2006; Buse et al., 2007), which is
desirable; however, the mean difference of 26.45 mg/dl between the two groups was statistically
significant, with the higher value residing in the IE group. Post-program, both groups’ mean
values were still below the <200 mg/dl mark (Table 4); the mean difference of 21.31 mg/dl
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between groups was again statistically significant, with a higher value present in the IE group.
However, mean change within groups was fairly similar statistically and clinically, with a 5.47
mg/dl reduction in the IE group and a less than 0.5 mg/dl decrease in the GE group (Table 6).
These constancies are likely explained by the rise and fall of LDL and TG within groups.
HDL values similarly remained fairly constant, with no statistically significant
differences between groups present at pre- or post-program. Within groups, a slight decrease of
0.56 mg/dl was noted in the IE group and a slight increase of 2.72 mg/dl in the GE group from
pre- to post-program (Table 6). Although analysis by gender was not performed, it should be
noted that a statistically significant improvement in HDL did not occur for either education
group as a whole; therefore, significant improvements within groups by gender are unlikely.
However, it is possible that separate analyses by gender might have provided further clarification
as to whether or not female patients within the two groups had achieved or not achieved the
recommended HDL goal of >50 mg/dl (Solano & Goldberg, 2006; Buse et al., 2007) pre- and/or
post-program, seeing as the means for both groups at pre- and post-program measured >40
mg/dl.
LDL data, in contrast, presented unique results. While the 32.94 mg/dl pre-program
difference between groups was statistically significant (Table 3), the post-program difference of
17.15 mg/dl was not, although it was quite close (Table 4). Within groups, both pre- and postprogram values in the IE group measured above the target value of <100 mg/dl (Solano &
Goldberg, 2006; Buse et al., 2007), but a decrease of 13.96 mg/dl from pre- to post-program did
occur (Table 6). In contrast, pre- and post-program GE group values measured less than the <100
mg/dl target, but a very slight increase of 1.83 mg/dl was noted from pre- to post-program (Table
6). From the data available, it appears that patients in the individual group may have benefitted
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slightly from their initial appointments by a small LDL reduction, although their mean preprogram LDL value was higher than that of the GE group, and they did not reach the target goal
of <100 mg/dl.
Lastly, TG values did not demonstrate a statistically significant pre-program difference
between groups (Table 3), although the post-program difference was more pronounced but still
insignificant (Table 4). Clinically, however, within-group changes do stand out. From pre- to
post-program, mean TG in the IE group increased by 25.99 mg/dl; both pre- and post-program
values were above the recommended target of <150 mg/dl (Table 6) (Solano & Goldberg, 2006;
Buse et al., 2007). Unlike the trend in the IE group, mean TG value in the GE group began above
the <150 mg/dl mark at pre-program but decreased by 26.83 mg/dl to just under the <150 mg/dl
goal at 148.05 mg/dl (Table 6). As the GE group’s pre-program value was higher than the IE
group’s (Table 3), the clinically significant reduction in the GE group suggests that benefits of
the diabetes education were more pronounced in that group.
In comparison to the limited literature on the subject of lipid values as outcome results
from DSME (Liu et al., 2014; Tshiananga et al., 2012; Davis et al., 2010), results from this study
seem to suggest a partial departure from the assumed pattern of beneficial changes in these
measures. While the previously mentioned studies (Liu et al., 2014; Tshiananga et al., 2012;
Davis et al., 2010) generally indicated statistically significant improvements in one or more
parameters after an education program, either within the same group or as opposed to a control
group, the GE group, who had attended the entire DSME program, did not demonstrate clinically
significant changes in TC, HDL, or LDL from pre- to post-program or statistically significant
changes when compared to the IE group, although TG did improve clinically but not
significantly in comparison to that of the IE group.
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Yet in comparison to the standards recommended for reducing the risk of CVD (Solano
& Goldberg, 2006; Buse et al., 2007), the GE group certainly demonstrated a more noticeable
improvement overall. As shown in Table 6, the GE group’s lipid values generally trended in a
more protective direction than did those of the IE group, as evidenced by an upward trend in
HDL, a nearly stationary LDL that remained within the target limit (Solano & Goldberg, 2006;
Buse et al., 2007), and a clinically significant decrease in TG to below the target limit (Solano &
Goldberg, 2006; Buse et al., 2007). In contrast, the IE group evidenced a decrease in HDL, an
LDL that remained above the target limit (Solano & Goldberg, 2006; Buse et al., 2007) although
it did decrease, and a TG count that increased even farther above the target limit (Solano &
Goldberg, 2006; Buse et al., 2007). Although a statistically significant difference in TC was
obvious between the groups, the general trend toward improvement in the GE group versus the
mixed results in the IE group implies that the GE group likely reduced their risk of CVD to a
degree, while the IE group probably did not. These findings further support the PSJMC DSMT
program’s effectiveness as a whole and suggest that completion may be associated with riskreducing improvements in lipid profiles.
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Chapter 6: Conclusions
Summary and Conclusions
Although the study results did not statistically support the original hypothesis, they
nonetheless provided valuable insight into the topic of DSME program completion in several
ways. First, the analysis of HbA1c changes both between and within groups provides evidence
that the PSJMC DSMT program does play a role in the lowering of this laboratory measure, even
to the point of clinical significance (Buse et al., 2007). Between groups, the values do trend in
the direction anticipated of them—namely, that participants in the IE group would, by nature of
not having completed the full program and likely demonstrating less compliance as a whole,
display a higher average HbA1c value than that of participants in the GE group. Within groups,
the reduction in the GE group to a level considered clinically significant may be an added benefit
for those patients who completed the entire educational program. Also, patients in the IE group
who attended only the initial individual session still appeared to benefit by a greater than 1%
reduction in this value. While statistical significance is important, the clinical significance of
these changes should not be overlooked, as they are substantial for both groups in this study and
have the potential to improve health outcomes through the reduction of vascular complications
(Skyler et al., 2009).
Second, in regards to lipid values, the large amount of missing data makes it difficult to
draw definitive conclusions from this study. However, it does appear that both groups may have
derived a very slight benefit from the education in different ways. In the IE group, the one
noticeable benefit was the slight reduction in LDL, the type of lipoprotein that has been
implicated in increasing the risk of CVD (Gropper & Smith, 2013). However, opposing that
reduction were a concomitant rise in TG, of which increased concentrations also may play a role
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in the development of CVD (Do et al., 2013), and a slight decrease in the cardio-protective HDL
(Gropper & Smith, 2013). This group’s TC did decrease slightly overall, which may imply at
least a minimal amount of improvement after one educational session. As for the GE group,
potential benefits include the slight increase in HDL and the clinically significant decrease in
TG, both of which may assist with reducing the risk of CVD (Do et al., 2013; Gropper & Smith,
2013). It should be noted that LDL did increase very slightly but was still under the clinical
threshold both pre- and post-program in this group.
Third, although the disease process and exact time of diagnosis were not collected due to
the fact that they were not uniformly available in the charts, many patients’ chart notes included
references to the fact that they were fairly newly diagnosed, such that this was likely true of the
majority of patients in the DSMT program as a whole. These findings indicate that
DSME/DSMT programs may provide substantial clinical benefits for recently diagnosed
patients.
Fourth, while the purpose of the study was not to compare the relative availability of
laboratory values between groups, it was nevertheless observed that participants in the IE group
generally tended to have fewer laboratory values available than participants in the GE group,
both pre- and post-program as well as for complete pre- to post-program sets. This phenomenon
occurred even after the primary care providers of all patients with missing laboratory values were
contacted, which suggests that barriers that prevent compliance to full program attendance may
also be at work in regards to these patients’ follow-up with their providers. These findings align
with Duncan and colleagues’ correlation between frequency of HbA1c and lipid testing and
number of episodes of diabetes education (Duncan et al., 2011).
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In conclusion, the results from this study present a comparative picture of patients’
laboratory responses based on grouping by educational extremes in the newly restructured
PSJMC DSMT program during the past year. As the program continues to grow, more data will
be available in the coming years to confirm or deny the present findings and to determine the
program’s success in the long term.
Limitations of the Study
As has been implied, several limitations exist within this study. Availability of patient
laboratory values was a prominent one, especially in the IE group. This occurred because many
of these patients did not have regular follow-up visits with their physicians and/or the physicians
did not order an analysis of the specific variables in this study at the time blood work was
performed. As this factor was out of the control of the PI and the CDE, the actual effect of either
type of education may never be fully known. Future, larger studies may attempt to ascertain
program efficacy with more confidence.
Second, differences in the availability of patient data for the pre- and post-program
calculations versus the data available for change score calculations may have contributed to
discrepancies regarding the actual efficacy of the program. As it was originally anticipated that
more data would be available than the data that were actually present, the proposed plan of
analysis was kept for pre- and post-program comparisons in an attempt to maintain adequate
statistical power. Unfortunately, the general lack of data resulted in very few values available for
the change score calculations, which require a complete set of pre- and post-program values. As
a result, averaging the small number of scores resulted in high variability with large standard
deviations. Again, larger studies may display better results from this procedure.

50

Third, medication usage information was not collected for pharmacotherapy agents. The
extent to which patients were prescribed these medications, especially those for lipid control, as
well as the extent to which the medications influenced the study results is unknown.
Fourth, previous diabetes-related knowledge within patient groups is relatively unknown.
Patients’ “yes” responses to the question of having received previous diabetes education were
marked by uncertainty, and the question itself did not address knowledge obtained by the patient
through means other than that of formal diabetes education delivered by a healthcare
professional. It is very possible that knowledge obtained through other means assisted the
movement of laboratory values in a favorable direction.
Fifth, it is possible that the significant difference in demographic information (i.e., age
and BMI) between the two groups may have influenced the end results. Although it appears that
BMI has not been studied in correlation to HbA1c levels in established T2DM, there may be a
relationship that research has yet to uncover which could have affected the IE group participants’
success. As post-program BMI was generally unavailable in patient records, that relationship
could be explored in future studies.
Implications
This study’s results demonstrate that the PSJMC DSMT program does effectively assist
with the improvement of HbA1c and lipids in a clinically significant manner in participants who
complete the entire program. It may also be implied that participants who attend even the initial
educational session may derive some clinical benefit from the introductory material covered in
the session. As such, the CDE can continue to use the current schedule and materials for the
individual appointments and classes and refine them as needed. All patients should continue to
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be encouraged to attend classes if at all possible in order to receive the full benefits of the
education.
In addition to providing the PSJMC DSMT program with outcomes data, these findings
also contribute to the body of research specifically surrounding AADE-accredited DSME
programs. This research supports the effectiveness of the organization’s program accreditation
standards in their ability to produce positive changes in patients with DM and may serve as an
example for other programs in regards to methods of creating and presenting educational
curricula.
Future Research
Based on these findings, further studies may be performed to quantify the clinical results
of dropping out of versus completing a DSME program on a larger scale, both at PSJMC and
nationwide. Additional comparisons could be made regarding number of educational sessions
attended and degree of effectiveness to determine the success rates of participants who drop out
of programs at varying points in time. When more definitive data is obtained on this topic, efforts
could focus upon developing other educational materials and strategies to address the barriers
that seem to hinder many past, current, or prospective participants.
Furthermore, cost analysis research continues to be needed in this field (Boren et al.,
2009), and accredited programs such as this may serve as a ready supply of information, upon
which more detailed studies and organization-wide policies may build. Further cost-effectiveness
studies may also provide continuing support for current service reimbursement policies.
Last, a method of addressing barriers in communication with providers and the process of
obtaining laboratory values in a timely manner is needed. As technology continues to improve,
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so may the ease of obtaining necessary information. This topic should certainly be one of those
focused upon by information technology specialists in the coming years.

53

References
Action to Control Cardiovascular Risk in Diabetes Study Group. (2008). Effects of intensive
glucose lowering in type 2 diabetes. New England Journal of Medicine, 358, 2545-2559.
ADVANCE Collaborative Group. (2008). Intensive blood glucose control and vascular outcomes
in patients with type 2 diabetes. New England Journal of Medicine, 358, 2560-2572.
American Diabetes Association. (2014a). Diagnosis and classification of diabetes mellitus.
Diabetes Care, 37(1), S81-S90.
American Diabetes Association. (2014b). Standards of medical care in diabetes. Diabetes Care,
37, S14-S80.
American Diabetes Association. (2014c). Statistics about diabetes. Retrieved from American
Diabetes Association website: http://www.diabetes.org/diabetes-basics/statistics/
American Diabetes Association. (2015). Standards of medical care in diabetes: Classification and
diagnosis of diabetes. Diabetes Care, 38, S8-S16.
American Heart Association. (April 21, 2014). What your cholesterol levels mean. Retrieved
from American Heart Association website:
http://www.heart.org/HEARTORG/Conditions/Cholesterol/AboutCholesterol/WhatYour-Cholesterol-Levels-Mean_UCM_305562_Article.jsp
Boren, S.A., Fitzner, K.A., Panhalkar, P.S., & Specker, J.E. (2009). Costs and benefits associated
with diabetes education: A review of the literature. The Diabetes Educator, 35(1), 72-96.
Brown, H.S., Wilson, K.J., Pagan, J.A., Arcari, C.M., Martinez, M., Smith, K., & Reininger, B.
(2012). Cost-effectiveness analysis of a community health worker intervention for lowincome Hispanic adults with diabetes. Preventing Chronic Disease, 9.
doi:10.5888/pcd9.120074

54

Buse, J.B., Ginsberg, H.N., Bakris, G.L., Clark, N.G., Costa, F., Eckel, R., . . . Stone, N.J.
(2007). Primary prevention of cardiovascular diseases in people with diabetes mellitus: A
scientific statement from the American Heart Association and the American Diabetes
Association. Diabetes Care, 30(1), 162-172.
Campbell, E.M., Moffitt, P., & Sanson-Fisher, R.W. (1996). The relative effectiveness of
educational and behavioral instruction programs for patients with NIDDM: A randomized
trial. The Diabetes Educator, 22(4), 379-386.
Centers for Disease Control and Prevention. (2014). National diabetes statistics report, 2014:
Estimates of diabetes and its burden in the United States. Atlanta, GA: U.S. Department
of Health and Human Services, Centers for Disease Control and Prevention. Retrieved
from http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html
Clark M. (2008). Diabetes self-management education: A review of published studies. Primary
Care Diabetes, 2(3), 113-120.
Cochran, J., & Conn, V.S. (2008). Meta-analysis of quality of life outcomes following diabetes
self-management training. The Diabetes Educator, 34(5), 815-823.
Dalmau-Llorca, M.R., Garcia-Bernal, G., Aguilar-Martin, C., & Palau-Galindo, A. (2003).
Group versus individual education for type-2 diabetes patients. Aten Primaria, 32(1), 3641.
Davis, R.M., Hitch, A.D., Salaam, M.M., Herman, W.H., Zimmer-Galler, I.E., & Mayer-Davis,
E.J. (2010). TeleHealth improves diabetes self-management in and underserved
community: Diabetes TeleCare. Diabetes Care, 33(8), 1712-1717.

55

Deakin, T., McShane, C.E., Cade, J.E., & Williams, R.D. (2005). Group based training for selfmanagement strategies in people with type 2 diabetes mellitus. Cochrane Database
Systematic Reviews, 18(2). doi: 10.1002/14651858.CD003417.pub2
de Groot, M., Doyle, T., Kushnick, M., Shubrook, J., Merrill, J., Rabideau, E., & Schwartz, F.
(2012). Can lifestyle interventions do more than reduce diabetes risk? Treating
depression in adults with type 2 diabetes with exercise and cognitive behavioral therapy.
Current Diabetes Reports, 12, 157-166.
Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive
treatment of diabetes on the development and progression of long-term complications in
insulin-dependent diabetes mellitus. New England Journal of Medicine, 329, 977-986.
Do, R., Willer, C.J., Schmidt, E.M., Sengupta, S., Gao, C., Peloso, G.M., . . . Kathiresan, S.
(2013). Common variants associated with plasma triglycerides and risk for coronary
artery disease. Natural Genetics, 45(11), 1345-1352.
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D., . . . Huang, G.D.
(2009). Glucose control and vascular complications in veterans with type 2 diabetes. New
England Journal of Medicine, 360(2), 129-139.
Duncan, I., Ahmed, T., Li, Q.E., Stetson, B., Ruggiero, L., Burton, K., . . . Fitzner, K. (2011).
Assessing the value of the diabetes educator. The Diabetes Educator, 37(5), 638-657.
Eddy, D.M., Schlessinger, L., & Kahn, R. (2005). Clinical outcomes and cost-effectiveness of
strategies for managing people at high risk for diabetes. Annals of Internal Medicine,
143(4), 251-264.

56

Fisher, L., Hessler, D., Glasgow, R.E., Arean, P.A., Masharani, U., Naranjo, D., & Strycker,
L.A. (2013). REDEEM: A pragmatic trial to reduce diabetes distress. Diabetes Care, 36,
2551-2558.
Gary, T.L., Genkinger, J.M., Gualiar, E., Peyrot, M., & Brancati, F.L. (2003). Meta-analysis of
randomized educational and behavioral interventions in type 2 diabetes. The Diabetes
Educator, 29(3), 488-501.
Goldin, A., Beckman, J.A., Schmidt, A.M., & Creager, M.A. (2006). Advanced glycation end
products: Sparking the development of diabetic vascular injury. Circulation, 114, 597605.
Gropper, S.S., & Smith, J.L. (2013). Advanced nutrition and human metabolism (6th ed.).
Belmont, CA: Wadsworth Cengage Learning.
Healy, S.J., Black, D., Harris, C., Lorenz, A., & Dungan, K.M. (2013). Inpatient diabetes
education is associated with less frequent hospital readmission among patients with poor
glycemic control. Diabetes Care, 36(10), 2960-2967.
Hermanns, N., Schmitt, A., Gahr, A., Herder, C., Nowotny, B., Roden, M., . . . Kulzer, B.
(2015). The effect of a diabetes-specific cognitive behavioral treatment program
(DIAMOS) for patients with diabetes and subclinical depression: Results of a randomized
controlled trial. Diabetes Care, 38, 551-560.
Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., & Neil, A.W. (2008). 10-year followup of intensive glucose control in type 2 diabetes. New England Journal of Medicine,
359, 1577-1589.

57

Jarvis, J., Skinner, T.C., Carey, M.E., & Davies, M.J. (2010). How can structured selfmanagement patient education improve outcomes in people with type 2 diabetes?
Diabetes, Obesity & Metabolism, 12(1), 12-19.
Kantharidis, P., Wang, B., Carew, R.M., & Lan, H.Y. (2011). Diabetes complications: The
microRNA perspective. Diabetes, 60(7), 1832-1837.
Liu, L., Lee, M.J., & Brateanu, A. (2014). Improved A1c and lipid profile in patients referred to
diabetes education programs in a wide health care network: A retrospective study.
Diabetes Spectrum, 27(4), 297-303.
Mayo Clinic Staff. (July 31, 2014). Diabetes risk factors. Retrieved from Mayo Clinic website:
http://www.mayoclinic.org/diseases-conditions/diabetes/basics/risk-factors/con20033091
Mendoza, M., & Rosenberg, T. (2013). Self-management of type 2 diabetes: A good idea – or
not? The evidence supports the use of some measures but is questionable on others,
including routine self-monitoring of blood glucose. The Journal of Family Practice,
62(5), 244-248.
Michigan Diabetes Research and Training Center. (2014). Hemoglobin A1c fact sheet. Retrieved
from University of Michigan Health System website:
http://www.med.umich.edu/mdrtc/cores/chemcore/hemoa1c.htm
Nathan, D.M., Cleary, P.A., Backlund, J.Y., Genuth, S.M., Lachin, J.M., Orchard, T.J., . . .
Zinman, B. (2005). Intensive diabetes treatment and cardiovascular disease in patients
with type 1 diabetes. New England Journal of Medicine, 353(25), 2643-2653.
Nelms, M., Sucher, K.P., Lacey, K., & Roth, S.L. (2011). Nutrition therapy and pathophysiology
(2nd ed.). Belmont, CA: Brooks/Cole Cengage Learning.

58

Norris, S.L., Lau, J., Smith, S.J., Schmid, C.H., & Engelgau, M.M. (2002). Self-management
education for adults with type 2 diabetes: A meta-analysis of the effect on glycemic
control. Diabetes Care, 25(7), 1159-1171.
Powers, M.A., Bardsley, J., Cypress, M., Duker, P., Funnell, M.M., Fischl, A.H., . . . Vivian, E.
(2015). Diabetes self-management education and support in type 2 diabetes: A joint
position statement of the American Diabetes Association, the American Association of
Diabetes Educators, and the Academy of Nutrition and Dietetics. Journal of the Academy
of Nutrition and Dietetics, 155(8), 1323-1334.
Prezio, E.A., Pagan, J.A., Shuval, K., & Culica, D. (2014). The Community Diabetes Education
(CoDE) Program: Cost effectiveness and health outcomes. American Journal of
Preventative Medicine, 47(6), 771-779.
Rickheim, P.L., Weaver, T.W., Flader, J.L., & Kendall, D.M. (2002). Assessment of group
versus individual diabetes education: A randomized study. Diabetes Care, 25(2), 269274.
Robbins, J.M., Thatcher, G.E., Webb, D.A., & Valdmanis, V.G. (2008). Nutritionist visits,
diabetes classes and hospitalization rates and charges: The Urban Diabetes Study.
Diabetes Care, 31(4), 655-660.
Siminerio, L., Ruppert, K., Huber, K., & Toledo, F.G. (2014). Telemedicine for Reach,
Education, Access, and Treatment (TREAT): Linking telemedicine with diabetes selfmanagement education to improve care in rural communities. The Diabetes Educator, 40,
797-805.
Skyler, J.S., Bergenstal, R., Bonow, R.O., Buse, J., Deedwania, P., Gale, E.A., . . . Sherwin, R.S.
(2009). Intensive glycemic control and the prevention of cardiovascular events:

59

Implications of the ACCORD, ADVANCE, and VA diabetes trials. A position statement
of the American Diabetes Association and a scientific statement of the American College
of Cardiology Foundation and the American Heart Association. Diabetes Care, 32(1),
187-192.
Solano, M.P., & Goldberg, R.B. (2006). Lipid management in type 2 diabetes. Clinical Diabetes,
24(1), 27-32.
Spellman, C.W. (2010). Pathophysiology of type 2 diabetes: Targeting islet cell dysfunction.
Journal of the American Osteopathic Association, 110(3), S2-S7.
Steinsbekk, A., Rygg, L.O., Lisulo, M., Rise, M.B., & Fretheim, A. (2012). Group based
diabetes self-management education compared to routine treatment for people with type 2
diabetes mellitus: A systematic review with meta-analysis. BMC Health Services
Research, 12(213). doi:10.1186/1472-6963-12-213
Stratton, I.M., Adler, A.I., & Neil, H.A.W. (2000). Association of glycaemia with macrovascular
and microvascular complications of type 2 diabetes (UKPDS 35): Prospective
observational study. BMJ, 321(405). doi:http://dx.doi.org/10.1136/bmj.321.7258.405
Tang, T.S., Funnell, M.M., & Oh, M. (2012). Lasting effects of a 2-year diabetes selfmanagement support intervention: Outcomes at 1-year follow-up. Prevention of Chronic
Disease, 9, E109. doi:10.5888/pcd9.110313
Thorpe, C.T., Fahey, L.E., Johnson, H., Deshpande, M., Thorpe, J.M., & Fisher, E.B. (2013).
Facilitating healthy coping in patients with diabetes: A systematic review. The Diabetes
Educator, 39(1), 33-52.

60

Toledo, F.G.S., Ruppert, K., Huber, K.A., & Siminerio, L.M. (2014). Efficacy of the
Telemedicine for Reach, Education, Access, and Treatment (TREAT) model for diabetes
care. Diabetes Care, 37(8), e179-e180. doi:10.2337/dc13-1909
Toobert, D.J., Glasgow, R.E., Strycker, L.A., Barrera, M., Radcliffe, J.L., Wander, R.C., &
Bagdade, J.D. (2003). Biologic and quality-of-life outcomes from the Mediterranean
Lifestyle Program: A randomized clinical trial. Diabetes Care, 26(8), 2288-2293.
Toobert, D.J., Strycker, K.A., King, D.K., Barrera, M., Osuna, D., & Glasgow, R.E. (2011).
Long-term outcomes from a multiple-risk-factor diabetes trial for Latinas: ¡Viva Bien!
Translational Behavioral Medicine, 1(3), 416-426.
Torres, H.D., Franco, L.J., Stradioto, M.A., Hortale, V.A., & Schall, V.T. (2009). Evaluation of a
diabetes education program. Revista de Saude Publica, 43(2).
doi:http://dx.doi.org/10.1590/S0034-89102009005000001
Trento, M., Passera, P., Borgo, E., Tomalino, M., Bajardi, M., Cavallo, F., & Porta, M. (2004). A
5-year randomized controlled study of learning, problem solving ability, and quality of
life modifications in people with type 2 diabetes managed by group care. Diabetes Care,
27(3), 670-675.
Tshiananga, J.K., Kocher, S., Weber, C., Erny-Albrecht, K., Berndt, K., & Neeser, K. (2012).
The effect of nurse-led diabetes self-management education on glycosylated hemoglobin
and cardiovascular risk factors: A meta-analysis. The Diabetes Educator, 38(1), 108-123.
UK Prospective Diabetes Study Group. (1998). Intensive blood-glucose control with
sulphonylureas or insulin compared with conventional treatment and risk of
complications in patients with type 2 diabetes (UKPDS 33). The Lancet, 352(9131), 837853.

61

Urbanski, P., Wolf, A., & Herman, W.H. (2008). Cost-effectiveness of diabetes education.
Journal of the American Dietetic Association, 108(4), S6-S11.
van Belle, T.L., Coppieters, K.T., & von Herrath, M.G. (2011). Type 1 diabetes: Etiology,
immunology, and therapeutic strategies. Physiological Reviews, 91, 79-118.
Vithian, K., & Hurel, S. (2010). Microvascular complications: Pathophysiology and
management. Clinical Medicine, 10(5), 505-509.

62

APPENDICES

63

Appendix A: Eastern Michigan University Human Subjects Review Committee
Approval Letter

64

Appendix B: Eastern Michigan University Human Subjects Review Committee
Continuing Approval Letter

65

Appendix C: PSJMC Institutional Review Board Approval Letter

66

Appendix D: DSMT Initial Visit Form

67

68

69

70

71

72

73

74

